Added to YB: 2026-01-08
Pitch date: 2026-01-02
NOVO-B.CO [neutral]
Novo Nordisk A/S
+9.83%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.5T
Pitch Price
DKK 333.60
Price Target
N/A
Dividend
3.36%
EV/EBITDA
9.64
P/E
14.86
EV/Sales
5.10
Sector
Pharmaceuticals
Category
growth
Theodosian Capital | Stocks Update 2/1/2026 - Novo Nordisk A/S
NOVO-B.CO (updatE): FDA approved first daily oral GLP-1 Wegovy pill for weight management, launching Jan 2025. Awaiting EU approval to expand market. Stock +10% on news. Trades 14.0x 2027 consensus earnings, 3.7% yield - cheap for large pharma but execution critical.
Read full article (1 min)